Vanguard Group Inc Revance Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,398,406 shares of RVNC stock, worth $13.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,398,406
Previous 5,069,625
6.49%
Holding current value
$13.9 Million
Previous $44.6 Million
40.4%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding RVNC
# of Institutions
215Shares Held
83.4MCall Options Held
656KPut Options Held
424K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.31MShares$18.8 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.28MShares$16.1 Million0.01% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.25MShares$13.5 Million3.02% of portfolio
-
Polar Capital Holdings PLC London, X03.88MShares$9.98 Million0.12% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...